Endocrine Abstracts

The introduction of immune checkpoint inhibitors (ICIs) in clinical management of cancer has had an undeniable impact in management of cancer patients. Currently there are several ICIs are used across Europe including but not limited to, pembrolizumab, atezolizumab, and ipilimumab. Even though their clinical efficacy is reputable, they have the potential of causing serious immunotherapy-related adverse events’ (irADRs) in several organ systems including endocrine organs. ...